Shares of Advancis Pharmaceutical were sinking this morning after the drug developer announced its Amoxicillin PULSYS Phase III clinical trial for pharyngitis/tonsillitis due to strep throat failed to hit its primary endpoint. The trial compared Advancis' Amoxicillin PULSYS 775 mg tablet dosed once-daily for seven days to 250 mg of penicillin VK dosed four times daily for 10 days. According to top-line trial data, Amoxicillin PULSYS failed to demonstrate statistical non-inferiority to the comparator therapy in the primary endpoint: bacterial eradication at the post-therapy test-of-cure visit for patients who successfully completed the trial protocol. Advancis has been developing the therapy with Par.
- read this press release for more